Related Experiment Video
Updated: Aug 5, 2026

Computer-Aided Three-Dimensional Visualization in the Treatment of Locally Advanced Thyroid Cancer
Published on: June 9, 2023
Advanced Thymoma and Advanced Thymic Carcinoma Treatment Practices in 2018-2022: A Nationwide Analysis in Japan
Junichi Ishigaki1,2,3, Ryoko Rikitake1,4, Hidenori Kage2
1Department of Public Health and Health Policy, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Introduction:
Thymomas and thymic carcinomas are rare diseases with limited clinical evidence. This study aimed to investigate the clinical characteristics of and treatment practices for Stages III and IV thymoma or thymic carcinoma in Japan.
Methods:
We analyzed cases of Stage III and IV thymoma and thymic carcinoma diagnosed between 2018 and 2022 and recorded in a nationwide dataset linking the Hospital-based Cancer Registry and the Diagnosis Procedure Combination survey. Treatment practices, including the use of perioperative chemotherapy, radiotherapy, and newer systemic therapies as well as the chemotherapy regimens, were evaluated.
Results:
Overall, 556 stage III thymoma, 312 stage III thymic carcinoma, 431 stage IV thymoma, and 976 stage IV thymic carcinoma patients were identified. Postoperative radiotherapy after complete resection was more common for stage III thymic carcinoma than for thymoma (34.1% vs. 10.7%), while perioperative chemotherapy was used more frequently for stage IV thymoma than for thymic carcinoma (preoperative: 15.5% vs. 3.7%; postoperative: 8.4% vs. 4.4%). For stage IV thymoma, adriamycin-cisplatin-vincristine-cyclophosphamide was the most common regimen (41.8%), whereas carboplatin-paclitaxel was predominantly used for stage IV thymic carcinoma (99.5%). The proportion of anthracycline-based therapy for stage IV thymoma increased from 50.0% to 77.8%, while that of postoperative radiotherapy for stage III thymoma decreased from 11.1% to 4.1%.
Conclusions:
Evidence-based treatment approaches for thymoma and thymic carcinoma have been widely adopted in Japan.
Related Concept Videos
Tumor Immunotherapy
Treatment Resistant Cancers
Treatment Resistent Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Tumor Progression
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
